Combination Treatment of IL‐17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review
Immunity, Inflammation and Disease · 2026
DOI: 10.1002/iid3.70515 ↗Kurz gefasst
Fallbericht in der Zeitschrift Immunity, Inflammation and Disease, 2026. Verfasst von Mengduan Pang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, First Affiliated Hospital of Dalian Medical University, Dalian, China. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Interleukin-17, Janus Kinase Inhibitors, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Psoriatic arthritis (PsA) is a chronic inflammatory disease with complex pathophysiology. Despite advancements in biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs), treatment responses remain suboptimal for many patients.
Methods
We present a case of a 35‐year‐old male with refractory PsA who achieved significant clinical improvement through combination therapy with ixekizumab (an IL‐17 inhibitor) and upadacitinib (a JAK inhibitor), following inadequate responses to multiple monotherapies. A scoping review of the literature was conducted, analyzing studies on dual b/tsDMARD therapy in PsA.
Results
The patient achieved rapid clinical improvement with complete resolution of articular symptoms, normalization of inflammatory markers, and significant metabolic improvements. The scoping review identified 16 studies, highlighting the potential of multi‐target strategies while emphasizing safety concerns such as increased infection risks.
Conclusion
This case and review underscore the promise of combination therapy in PsA while emphasizing the need for further research to optimize its use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
ORCID-Profile: Mengduan Pang, Ling Li, Qi Zhang, Min Zhao
Zitieren
APA
Pang, M., Li, L., Zhang, Q., & Zhao, M. (2026). Combination Treatment of IL‐17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70515
Vancouver
Pang M, Li L, Zhang Q, Zhao M. Combination Treatment of IL‐17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review. Immunity, Inflammation and Disease. 2026. doi:10.1002/iid3.70515
BibTeX
@article{Pang2026,
author = {Pang, Mengduan and Li, Ling and Zhang, Qi and Zhao, Min},
title = {Combination Treatment of IL‐17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review},
journal = {Immunity, Inflammation and Disease},
year = {2026},
doi = {10.1002/iid3.70515}
}
EUVIMED